

Dana E. Al-Ansari<sup>1,2,3</sup>, Nura M. Adam<sup>1</sup>, Isra Marei<sup>3</sup>, Huseyin Yalcin<sup>2</sup> and Haissam Abou Saleh<sup>1,2</sup>

<sup>1</sup> Department of Biological and Environmental Sciences, Qatar University, Doha, Qatar.

<sup>2</sup> Biomedical Research Center, Qatar University, Doha, Qatar

<sup>3</sup> Weill Cornell Medicine-Qatar, Doha, Qatar.

Faculty & Postdocs  
Population, Health and Wellness


## Introduction

Cardiovascular diseases (CVDs) are considered the major cause of death worldwide. Therapeutic delivery to the cardiovascular system may play an important role in the successful treatment of a variety of CVDs, including atherosclerosis, ischemic-reperfusion injury, and microvascular diseases. Despite their clinical benefits, current therapeutic drugs are hindered by their short half-life and systemic side effects. This limitation could be overcome using controlled drug release with the potential for targeted drug delivery using a nanomedicine approach. In the current study, we have assessed the use of a highly porous nano-sized preparation of iron-based Metal-organic Framework (MOF) commonly referred to as nanoMIL-89 as potential drug carriers in the cardiovascular system.

## Objectives


- To assess the effect of nanoMIL-89 on the viability and cytotoxicity of human vascular cells and the cellular uptake *in vitro*
- To evaluate the organ-system toxicity of nanoMIL-89 *in vivo* using the Zebrafish model.

## In vitro




## Methodology


## In vivo



## Results




**Figure 1.** The viability, cytotoxicity and anti-inflammatory effects of nanoMIL-89 on (A,B,C) PAECs and (E,D,F) PSMCs using AlamarBlue®, LDH and ELISA. Data are mean  $\pm$  SEM; n=3. (\*p<0.05).




**Figure 2.** Light microscope images (20X) showing the cellular uptake of nanoMIL-89 by PAECs and PSMCs at 72 hours post-treatment.


**Figure 3.** Z-stacked confocal images of PAECs (ctrl), (B) PAECs treated with 10µg/mL of nanoMIL-89 indicate the cellular up take of nanoMIL-89 in the cytoplasm. Channels used: Green; cytoskeleton, Red; cytoplasm, Blue; nucleus.





**Figure 4.** Scanning Transmission electron microscope images of (A,D) untreated PAECs and PSMCs sections. (B,E) PAECs and PSMCs treated with 5µg/mL nanoMIL-89 show the cellular internalization of nanoparticles. (C,F) Energy dispersive spectroscopy elemental mapping showing iron distribution of nanoMIL-89 in both cell types.



**Figure 5.** Zebrafish larvae (96 hpf) (a) Ctrl (b,c) treated with 300µM nanoMIL-89 stained with Prussian blue (black arrows).



**Figure 6.** The effect of increasing concentrations of nanoMIL-89 on the (A) viability and (B) hatching rate of zebrafish embryo at 72hpf. Data are mean  $\pm$  SEM; n=12. (\*p<0.05).



**Figure 7.** The effect of increasing concentrations of nanoMIL-89 on zebrafish embryos (A) blood flow, (B) heartbeats (C) ventricular volume and (D) cardiac output at 72hpf. Data are mean  $\pm$  SEM; n=4-6. (\*p<0.05).

## Conclusion

- nanoMIL-89 have no toxic effects on PAECs and PSMCs.
- nanoMIL-89 have anti-inflammatory effects as it significantly decreased the release of CXCL8 from PAECs and PSMCs.
- Confocal and TEM images showed high cellular uptake of nanoMIL-89 in PAECs and PSMCs.
- At concentrations  $\leq 30\mu\text{M}$ , nanoMIL-89 are relatively safe with no significant toxicity effect on Zebrafish embryos development.
- High concentrations ( $>100\mu\text{M}$ ) of nanoMIL-89 were observed to delay zebrafish hatching, increase their tail flicking activity at (24hpf) and may cause heart deformation which is currently under investigation using cardiotoxicity markers.
- nanoMIL-89 is a promising nanoparticle prototype for drug delivery in the cardiovascular system. Further investigations of MOFs, including diseased models and drug-loaded formulation is required.

## Acknowledgment

- This work was supported by QU student and Qatar National Research Fund grants: (UREP22-140-3-023) and (QUST-1-CAS-2019-6).
- We would like to acknowledge Dr. Jane Mitchell from Imperial College London for providing nanoMIL-89.